Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients.

In recent years, both dienogest, a fourth-generation progestin, and levonorgestrel-releasing intrauterine device have been found to be effective in terms of endometriosis-related pelvic pain improvement. No data, however, are available about their efficacy in terms of postoperative recurrence prevention in women recently submitted to surgery for endometriosis at every stage. Our objective was to compare two postoperative medical approaches for pain control and reduction of recurrences in patients undergoing surgery for endometriosis.
Ninety-two patients undergoing surgery for endometriosis and subsequent treatment by estradiol valerate + dienogest (EP) (group A) or levonorgestrel-releasing uterine device (LNG-IUD) (Group B) between January 2009 and June 2010 were retrospectively analyzed. The primary endpoints were pain relapse and disease recurrence rate at 12 and 24 months. The secondary endpoint was patient satisfaction with the therapy at 24 months.
Forty-eight patients in Group A and 44 in Group B were examined. At 12 and 24 months a statistically greater reduction both in Ca125 levels and VAS score was seen in women treated with EP compared to LNG-IUD. The recurrence rate at 12 and 24 months follow-up was slightly lower, but not at a significant level, in Group A than in Group B. Finally, satisfaction with treatment at 24 months was significantly higher in Group B.
EP administration is significantly more effective than LNG-IUD in reducing pelvic pain and more effective in reducing recurrence rate but not at a significant level. LNG-IUD, however, has significantly higher patient satisfaction.
AuthorsMichele Morelli, Angela Sacchinelli, Roberta Venturella, Rita Mocciaro, Fulvio Zullo
JournalThe journal of obstetrics and gynaecology research (J Obstet Gynaecol Res) Vol. 39 Issue 5 Pg. 985-90 (May 2013) ISSN: 1447-0756 [Electronic] Australia
PMID23551827 (Publication Type: Comparative Study, Journal Article)
Copyright© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.
Chemical References
  • Contraceptive Agents, Female
  • Drug Combinations
  • Estrogens
  • Receptors, Progesterone
  • estradiol Valerate, dienogest drug combination
  • Estradiol
  • Levonorgestrel
  • Nandrolone
  • Adult
  • Combined Modality Therapy
  • Contraceptive Agents, Female (administration & dosage, therapeutic use)
  • Drug Combinations
  • Endometriosis (physiopathology, prevention & control, surgery)
  • Estradiol (analogs & derivatives, therapeutic use)
  • Estrogens (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Intrauterine Devices, Medicated
  • Levonorgestrel (administration & dosage, therapeutic use)
  • Nandrolone (analogs & derivatives, therapeutic use)
  • Patient Satisfaction
  • Pelvic Pain (etiology, prevention & control)
  • Postoperative Care
  • Receptors, Progesterone (agonists)
  • Retrospective Studies
  • Secondary Prevention

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: